---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-074513"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2023-06-26T23:59:59+00:00"
generated_at: "2026-06-13T16:50:47.593120+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics reports non-clinical data showing MT-401 + HMA synergy; awarded $2M NIH grant

## Summary
- Non-clinical in vitro data: MT-401 after HMA (5'-Azacytidine) significantly decreased AML THP-1 cell growth vs. either agent alone, suggesting synergy.
- NIH SBIR grant of $2 million will fund a nationwide multi-center Phase 2b trial of MT-401 with HMA pre-treatment in AML patients post-HSCT.
- MT-401 targets four antigens (Survivin, PRAME, WT-1, NY-ESO-1); HMA upregulated Survivin expression in AML cells.
- Company plans to incorporate findings into current AML clinical study; revised design details expected in Q3 2023.

## SEC filing metadata
- accession: 0001104659-23-074513
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2023-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465923074513/0001104659-23-074513-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465923074513/tm2319618d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-074513
- JSON: https://secwatch.observer/filing/0001104659-23-074513.json
- Plain text: https://secwatch.observer/filing/0001104659-23-074513.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.